Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function. It will therefore aim to evaluate the incidence of acute kidney injury induced by fluorescein in diabetic patients with CKD. The objective is to determine the incidence, severity and risk factors associated with this deterioration to improve the care of this specific population.
>18 years old with type 2 or type 1 diabetes and chronic kidney disease stage 3b to 5 (eGFR<45 mL/min/1.73 m2)
Patients who do not give their consent
Patients who are allergic to fluorescein
Patients who are on dialysis
Patients who had fever, vomiting, diarrhea or any dehydration 48 hours before the intervention
Single group
Fluorescein angiography
Diagnostic testFluorescein angiography
Change in serum creatinine
Change in serum creatinine from baseline to day 4
Long-term change in serum creatinine
Change in serum creatinine from baseline to end of the third month
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
